Nelson Canales

🇭🇳🇪🇸
Urologist Endourology (ECIRS, HOLEP, MicroUSG) & UroOncology (NMIBC, MIBC, UTUC)
Member of Cueto & Guard Consortium

[GUARD Consortium @GuardConsortium]

La Mesa de Cáncer de Vejiga Avanzado del #GUARDSymposium2026 reúne a los Dres. Thomas Powles (@tompowles1), Urbano Anido (@urbano_anido) y Jonathan E. Rosenberg (@DrRosenbergMSK) para abordar secuenciación, ADCs y biomarcadores.

📅  18 sept. · Madrid.

Inscríbete AHORA, quedan pocos días ⤵️ https://t.co/lJFGffy0Qr

@DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @BerUrologia

[ICUA @ICUAurologia]

☀️ El Dr. Antonio Gómez Rodríguez, urólogo de ICUA, recuerda que muchas ETS pueden no presentar síntomas.

Usa preservativo, limita el alcohol, mantén al día tus vacunas y hazte pruebas tras relaciones sin protección o un cambio de pareja.

#ICUA #SaludSexual #ITS #ETS

[Asociación Andaluza de Urología @AAUrologia]

🗣️ II Curso Internacional de Enucleación Prostática Anatómica en Directo: Del Residente al Maestro.
📍Hospital Universitario de Jerez de la Frontera
🗓️ 12 al 14 de mayo de 2027. ¡RESERVA LA FECHA!
¡Así fue la primera edición! https://t.co/2Oz8tywz06

[Asociación Andaluza de Urología @AAUrologia]

🗣️ ¡Save the date!
Del 14 al 16 de octubre de 2026, #Granada acogerá el 38º Congreso de la @AAUrologia, un espacio de referencia para compartir conocimiento, impulsar la innovación y fortalecer la colaboración entre profesionales. https://t.co/dnzeS58UJF

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Pleased to share an outstanding collaborative review by @UrogerliMD @LauraBukavinaMD @CanDAydogdu @EUplatinum

Each histological subtype of bladder cancer behaves differently and deserves its own approach, not a one-size-fits-all approach.

Here we synthesize the latest data on this topic @PGrivasMDPhD @SpiessPhilippe @apolo_andrea @lianchengmd @AndreaNecchi et al

Full Text: https://t.co/WC5M50T19e
🧵 @IBCG_BladderCA

[MV Chandrakanth @ChandrakanthMv]

ASCO 2026 gave us Dato-DXd, SG, Daraxonrasib, CAR-T, bispecific antibodies, and many reasons for optimism.

The next morning in clinic, the questions are often different:

• Is the biopsy adequate?
• Can the patient tolerate treatment?
• Can they afford NGS?
• Will immunotherapy be covered?
• Is the drug even available?

Science is moving faster than ever.

Access, affordability, tissue adequacy, and performance status remain some of the biggest challenges in oncology.

#ASCO2026 #Oncology #CancerCare #MVOnco

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

The approval answers one question, but leaves another unanswered: which patients truly derive enough benefit to justify escalation beyond optimized BCG?

The FDA approval of durvalumab plus BCG in high-risk NMIBC was driven by a meaningful improvement in disease-free survival (HR 0.68), mainly recurrence free survival. Checkpoint inhibitors are not benign therapies, carrying ~ 15% risk of serious treatment-related adverse events.

At the same time, this trial also demonstrated that patients with BCG-naïve high-risk NMIBC have low rates of progression and bladder cancer mortality, when treated with BCG appropriately.

For many patients, the balance between reducing recurrence and exposing them to potentially significant toxicity is not straightforward.

That raises a practical question: who should actually receive treatment intensification?

[Félix Guerrero-Ramos @DrFelixGuerrero]

🚨A lot of new options for #BCGunresponsive NMIBC, but no direct comparisons
🤼We've tried to do some work on this, along with my friend @siadaneshmand and others
📖You can read it here @JUrology @AmerUrological @JUOpenPlus: https://t.co/Um9tDRn1UC
👀And much more to come!!!

[ICUA @ICUAurologia]

🔹El equipo de ICUA ha participado en el I Curso de Enucleación Prostática Anatómica en Directo: del Residente al Maestro, un encuentro formativo sobre técnicas avanzadas para el tratamiento quirúrgico de la hiperplasia benigna de #próstata.

#Urología #EnucleaciónProstática

[MV Chandrakanth @ChandrakanthMv]

KEYNOTE-B15 / EV-304 #ASCO2026

Perioperative EV + Pembrolizumab vs Gemcitabine + Cisplatin in cisplatin-eligible MIBC:

• 24-mo EFS: 79.4% vs 66.2% • HR for EFS: 0.53 • 24-mo OS: 86.9% vs 81.3% • pCR: 55.8% vs 32.5%

Key message: Strong perioperative efficacy signal with meaningful pCR improvement and emerging OS benefit.

Potential future perioperative standard in cisplatin-eligible bladder cancer.

#MVOnco #BladderCancer #ASCO2026 #UroOnc #Oncology #MedTwitter”

[scoffone cesare @scoffonecesare]

1st edition of the int. Enucleation meeting in Jerez de la Frontera. Fantastic, practical and interactive course.
https://t.co/UtYRGiiRVD @fgomsan @MartinCKanne @ThiagoHotaUro @alvarojuarezs
@quanta_system @LucaMartinel @Rochejeanbapti2

[Fernando GomezSancha @fgomsan]

Thanks to every faculty member who travelled. To Álvaro Juárez Soto and AAU. To the 75 urologists who packed the room and pushed every break.
We leave Jerez euphoric, energized, determined. Every patient in Spain deserves access to this technique.
We'll be back. 7/7

[Fernando GomezSancha @fgomsan]

Takeaways:
— En bloc enucleation can be learned during residency — Real-time OR supervision beats any wet lab — Tech adds value only on a clear anatomical concept — Honest school comparison raises every conversation — Institutional alignment matters 6/7

[Fernando GomezSancha @fgomsan]

The closing session was the most important: Heads of Urology of public hospitals across Andalusia at the same table, openly discussing how to consolidate anatomical enucleation in their services.
That doesn't happen every day. 5/7

[Fernando GomezSancha @fgomsan]

Day 2. Parallel live surgeries with @Alfonso_GimenoC (Madrid) and @ThiagoHotaUro (Brazil).
I lectured on laser physics. Javier Sánchez Macías (Barcelona) and I closed with two more live cases. 4/7

[Fernando GomezSancha @fgomsan]

Moisés Rodríguez Socarrás demonstrated microUS-guided focal cancer treatment combined with HoLEP — a live glimpse of where anatomical enucleation meets focal prostate oncology.
In front of 75 urologists. 3/7

[Fernando GomezSancha @fgomsan]

Day 1. Residents Belén Barba & Miguel Ugidos operated as primary surgeons under expert supervision.
International faculty in parallel ORs: Martin Kanne (Berlin), Julio Fernández del Álamo, Jean Baptiste Roche (Bordeaux), Cesare Scoffone (Turin), Nelson Canales. 2/7

[Fernando GomezSancha @fgomsan]

Two days. Live surgery. Residents operating as primary surgeons in front of an international faculty.
I AAU International Course on Anatomical Prostatic Enucleation — Hospital Universitario de Jerez. "From Resident to Master."

[Martin Kanne @MartinCKanne]

@urovivo23 I couldn‘t be happier about the possibility to participate! Thank you @BernardoNor9 so much! Meeting so many great people and learning so much is a privilege! @luisafo78490721 @2fabiosepulveda @thomastailly @fgomsan @GuidoGiusti and many more! Adiós Argentina! Volveré

[Martin Kanne @MartinCKanne]

On my way back home from a great 1st edition of the int. Enucleation meeting in Jerez de la Frontera. Teaching HoLEP is the key! Looking forward for many more editions in the future! https://t.co/z9Xdkedpw5 @fgomsan @scoffonecesare @ThiagoHotaUro @alvarojuarezs